Snakeroot: A Comprehensive Encyclopedic Reference
1. Nomenclature and Disambiguation
The common name "snakeroot" does not refer to a single botanical species. It is applied, often interchangeably, to several phylogenetically unrelated plants that share a historical association with snakebite treatment or a snake-like, twisted root morphology. The three most pharmacologically and historically significant plants bearing this name are:
- Black Snakeroot (Actaea racemosa L., synonym Cimicifuga racemosa [L.] Nutt.) — the most extensively researched species, from the family Ranunculaceae.
- Indian Snakeroot / Sarpagandha (Rauwolfia serpentina [L.] Benth. ex Kurz) — an Ayurvedic species from the family Apocynaceae, the source of the pharmaceutical alkaloid reserpine.
- Seneca Snakeroot / Senega Root (Polygala senega L.) — a North American species from the family Polygalaceae, used primarily as an expectorant.
A fourth plant, White Snakeroot (Ageratina altissima, formerly Eupatorium rugosum), also carries this common name but is highly toxic and is not used as a dietary supplement; it is discussed separately in the safety section for purposes of critical disambiguation.
This article covers each medicinally relevant species in turn, with sections on identity, traditional use, phytochemistry, scientific evidence, dosage, and safety.
2. Black Snakeroot (Actaea racemosa / Cimicifuga racemosa)
2.1 Botanical Identity and Common Forms
Actaea racemosa, also known as Cimicifuga racemosa, is a member of the buttercup family that grows in North America, and carries common names including black cohosh, black snakeroot, macrotys, bugbane, bugwort, rattleroot, and rattleweed. This member of the Ranunculaceae family produces towering white racemes that can reach 8 feet tall; native to rich, moist deciduous forests from southern Canada to northern Georgia, it has been treasured by Indigenous peoples for centuries as a powerful medicinal plant.
Extracts from the underground parts of the plant — the rhizome (Cimicifugae racemosae rhizoma) and the root (Cimicifugae racemosae radix) — are used in herbal medicine. The rhizomes and roots contain various saponins (triterpene saponins and triterpene glycosides, such as actein) as well as cimifugic acids and other phenol carboxylic acids.
Preparations of black cohosh are made from the roots and rhizomes. Black cohosh is considered an herbal remedy or dietary supplement. Common commercial forms include standardized dry root extracts in tablet or capsule form, fluid extracts, tinctures, and combination products. The most commonly studied black cohosh extracts (BCEs) in clinical trials are Remifemin® and Menofem/Klimadynon®. Remifemin® has changed formulation from a 60% ethanol extract to a 40% isopropanol extract, and the extract preparation is not consistently reported in trials.
2.2 Traditional and Historical Use
The first medicinal use of black cohosh is generally attributed to Native Americans, who used black cohosh for the treatment of a variety of disorders, including various conditions unique to women such as amenorrhea and menopause, rheumatism, kidney disorders, malaise, and pain during menses and childbirth.
Native Americans used black cohosh for treatment of a variety of conditions including kidney ailments, malaria, sore throat, and menstrual cramps. It has also been used medicinally in Germany since the late 19th century.
The Cherokee, Iroquois, and other tribes used the dark, gnarly rhizome extensively, calling it various names that translate to "rattle-top" for the sound made by its dried seed heads. Black cohosh root was an official drug (under the name "black snakeroot") in the United States Pharmacopoeia (USP) from 1820 to 1926.
In the 19th century, the root was used to treat snakebite, inflamed lungs, and pain from childbirth. Use of black cohosh was accepted and popularized by eclectic medical practitioners in the late 19th and early 20th centuries. With a shift toward evidence-based modern medicine, the use of black cohosh in America faded by the 1930s.
Traditional attributed properties include alterative, antidote, anti-inflammatory, antirheumatic, antispasmodic, astringent, cardiotonic, diaphoretic, diuretic, emmenagogue, expectorant, hypnotic, sedative, tonic, and vasodilatory actions. The medically active ingredients are not considered soluble in water, so a tincture of the root is normally used.
2.3 Key Phytochemical Constituents
The exact mechanism of action for black cohosh is not known. Some studies suggest that several biologically active substances are responsible for their action. A partial list of active compounds includes the isoflavone formononetin, isoferulic, caffeic, salicylic, and fukinolic acids. There are also miscellaneous fatty acids, tannins, and sugars. Phytosterin and resins that include Cimicifuga and triterpene glycosides are also present.
The compounds considered responsible for the therapeutic effect are triterpene glycosides, characterized by a cycloartane scaffold and a pentose moiety. The secondary metabolites actein and deoxyactein are triterpene glycosides and are among the compounds associated with the putative activity of black cohosh extracts. Actein and deoxyactein are used to standardize black cohosh supplements.
Eight new triterpene glycosides named cimiracemosides A–H, and eight known triterpene glycosides, have been isolated from rhizome extracts of black cohosh. Tissues and extracts of A. racemosa also contain tryptamine-derived compounds, such as serotonin analogs and β-carbolines. Of particular interest is the serotonin analog N-methylserotonin because it has highly potent serotonergic activity against the human 5-HT₇ receptor, making it a possible lead compound for explaining the mode of action of black cohosh–containing preparations in alleviating menopausal symptoms.
2.4 Proposed Mechanisms of Action
Multiple, potentially simultaneous mechanisms have been proposed. Most evidence points to several different mechanisms of action. Some researchers have shown evidence that it may exert its effects centrally through alterations in the serotonin pathways.
Because the opiate system in the brain is intimately associated with mood, temperature, and sex hormonal levels, the activity of black cohosh extracts at the human mu opiate receptor (hMOR) was investigated. The 100% methanol, 75% ethanol, and 40% 2-propanol extracts of black cohosh effectively displaced the specific binding of [³H]DAMGO to hMOR. Further studies of the clinically used ethanol extract indicated that black cohosh acted as a mixed competitive ligand, displacing 77 ± 4% [³H]DAMGO to hMOR (Ki = 62.9 μg/mL). Using the [³⁵S]GTPγS assay, the action of black cohosh was found to be consistent with an agonist, with an EC₅₀ of 68.8 ± 7.7 μg/mL. These results demonstrate for the first time that black cohosh contains active principle(s) that activate hMOR, supporting its beneficial role in alleviating menopausal symptoms.
Black cohosh was recently shown to have the beneficial effect of preventing bone loss. The compound 25-acetylcimigenol xylopyranoside (ACCX), a triterpenoid glycoside isolated from black cohosh, potently blocks in vitro osteoclastogenesis induced by either RANKL or TNFα. This represents a third putative mechanism — anti-osteoclastic activity — explored in preclinical research. It should be noted that these mechanistic studies are primarily in vitro or in animal models, and their direct relevance to human therapeutic effects has not been conclusively established.
Black cohosh is an agonist at several serotonin receptor subtypes, and inhibits CYP3A4 and CYP2D6. This latter pharmacokinetic property has clinical significance for drug interactions (see Safety section).
2.5 Scientific Evidence by Area of Use
2.5.1 Menopausal Vasomotor Symptoms (Hot Flashes, Night Sweats)
This is the most thoroughly studied application. A substantial number of studies in people have evaluated black cohosh for menopause symptoms.
A 2023 review of 22 studies of products containing black cohosh extracts, alone or in combination with other herbs, found that they were potentially beneficial for overall menopause symptoms. Data on specific symptoms showed improvements in hot flashes but not anxiety or depressive symptoms.
Black cohosh extracts have been associated with a reduction in the number of hot flashes in clinical studies. In a double-blind randomized study comparing placebo, conjugated estrogens, and black cohosh (preparation BNO 1055), the therapeutic effects of black cohosh were equally potent to conjugated estrogens in diminishing vasomotor symptoms (Wuttke, Seidlova-Wuttke, and Gorkow, 2003). Moreover, treatment with black cohosh had no effect on endometrial thickness, which was significantly increased among women receiving estrogen.
Findings from randomized trials suggest there may be a favorable effect of black cohosh for reducing vasomotor symptoms. For example, a network meta-analysis in women with an intact uterus found that, compared to placebo, black cohosh decreased vasomotor menopausal symptoms. However, black cohosh was not as effective as hormonal treatments.
Another large systematic review found benefit of isopropanolic black cohosh extract compared to placebo for psychological and neurovegetative symptoms (e.g., sleep, concentration, fatigue) of menopause. The product appeared to be more effective in higher doses or when combined with St. John's wort. Nonetheless, these findings are limited based on the lack of standardization of the supplement product used between studies.
A systematic review conducted on six randomized controlled trials (RCTs) with a total of 1,163 peri- and post-menopausal women concluded that the efficacy of black cohosh in reducing symptoms was currently not supported by fully conclusive evidence, and that further investigations were desirable. Another review of 16 studies addressing the weaknesses of previous studies and their heterogeneity found insufficient evidence to support the efficacy of black cohosh on early menopausal symptoms.
There is a growing literature on the efficacy of black cohosh for several menopausal symptoms, but when viewed in aggregate, the literature is equivocal. Some studies have reported a positive effect on specific symptoms while others have not.
Evidence strength: Moderate and mixed. Some individual RCTs and meta-analyses show benefit for hot flashes, but overall evidence is inconsistent due to heterogeneous preparations, dosing, and study populations. Black cohosh is not as effective as hormone therapy.
2.5.2 Bone Health
The triterpenoid glycoside 25-acetylcimigenol xylopyranoside (ACCX), isolated from black cohosh, potently blocks in vitro osteoclastogenesis induced by either RANKL or TNFα. This is a preclinical (in vitro) finding. Human clinical trial data specifically evaluating black cohosh's effect on bone mineral density as a primary outcome are limited, and this application cannot currently be considered supported by robust clinical evidence.
2.5.3 Breast Cancer–Related Hot Flashes
It is uncertain whether black cohosh can reduce hot flashes related to breast cancer treatment. Black cohosh is frequently studied as a complementary therapy for breast cancer patients and survivors to reduce vasomotor symptoms associated with treatment-induced menopause. However, this remains an area of active investigation without definitive evidence of efficacy or safety in this specific population.
2.5.4 Rheumatic and Musculoskeletal Conditions
Other uses of this herb include treating rheumatoid arthritis, musculoskeletal pain, and fever. These applications derive primarily from traditional use. Much less research has been done on black cohosh for conditions other than menopause symptoms. Clinical evidence for anti-rheumatic effects is essentially absent.
2.5.5 Cancer (In Vitro Research)
Some triterpenoids in black cohosh were found to exhibit relevant cytotoxic effects against human breast cancer cells. Subsequent studies with actein found that the inhibition of cell growth is associated with activation of specific stress response pathways and apoptosis, and that the compound alters the cell structure of MCF7 and MDA-MB-453 breast cancer cell lines. These are exclusively in vitro findings. No human clinical trials have evaluated black cohosh as a cancer treatment, and such use is not supported.
2.6 Dosage Forms and Reported Dosages
Numerous clinical trials and review articles seem to indicate that 40–80 mg daily of a standardized extract of black cohosh improves menopausal symptoms such as hot flashes. No serious side-event was reported even in a study using a higher dose of 128 mg/day standardized to 7.27 mg of triterpene glycosides (ethanolic extract of black cohosh).
A 75% ethanol extract, chemically standardized to 5.6% active triterpene glycosides and biologically standardized to the 5-HT₇ receptor, was used in a four-arm randomized double-blind and placebo-controlled Phase II clinical trial conducted by the UIC/NIH Center for Botanical Dietary Supplements Research.
2.7 Safety Considerations and Drug Interactions
Hepatotoxicity
Although case reports suggested connections between the use of dietary supplements containing black cohosh and liver damage, no evidence of hepatotoxicity — or any other form of serious toxicity — was found in systematic reviews of results from clinical trials of a chemically standardized black cohosh preparation; regardless of dosage administered, no liver function markers were altered. Reports of hepatic adverse effects include one case of acute liver failure, two cases of hepatitis (without further description), and two cases indicating mild elevation of liver function markers, though many of these patients were taking multiple botanical products simultaneously.
Analysis of 9 cases of suspected black cohosh hepatotoxicity using RUCAM (Roussel Uclaf Causality Assessment Method) suggested that none could be considered even possibly related, largely because of competing diagnoses, other medications being taken, and lack of information on course and outcome.
The U.S. Pharmacopeia (USP), based on a few case reports, has recommended that black cohosh products be labeled with a warning declaring that they may be hepatotoxic.
Common Adverse Effects
Black cohosh is well tolerated and is generally safe. However, some insignificant side effects, such as nausea, vomiting, headaches, and dizziness were reported.
Drug Interactions — Serotonergic Agents and CYP Enzymes
Female patients taking black cohosh to manage hot flashes and menopausal symptoms could be at risk for developing rhabdomyolysis and serotonin toxicity if they are also taking other serotonergic agents. A published case report describes a middle-aged woman who developed serotonin toxicity and rhabdomyolysis shortly after taking black cohosh supplements in the setting of long-term dual antidepressant use. Black cohosh is an agonist at several serotonin receptor subtypes, and inhibits CYP3A4 and CYP2D6, which can raise blood levels of drugs metabolized by those enzymes.
Contraindications
Black cohosh is contraindicated in patients with aspirin sensitivity, liver disease, hormone-sensitive cancers (e.g., certain kinds of breast cancer per animal data), stroke, or high blood pressure.
It is uncertain whether black cohosh is safe for women who have had hormone-sensitive conditions such as breast or uterine cancer. Black cohosh may not be safe for use during pregnancy or while breastfeeding.
3. Indian Snakeroot / Sarpagandha (Rauwolfia serpentina)
3.1 Botanical Identity and Common Forms
Rauwolfia serpentina (also spelled Rauvolfia serpentina) is a member of the Apocynaceae family and grows in tropical and subtropical regions of the Himalayas, Indian peninsula, Burma, Indonesia, and Sri Lanka. The plant is also known as Snakeroot, Sarpagandha, Chandrabagha, Chotachand, Chandrika, and Harkaya. The roots, leaves, and extracted juice are of medicinal importance as they contain many metabolites, particularly unique alkaloids.
Rauwolfia serpentina, native to the Indian subcontinent and Southeast Asia, has been used for centuries in traditional medicine systems of Ayurveda and Unani. It is an evergreen, perennial undershrub thriving in tropical and subtropical environments with moist, well-drained soils and moderate to high rainfall. The root is the primary medicinal component, typically ground into powder or processed into tablets and capsules, containing approximately 50 identified alkaloid compounds including reserpine, rescinnamine, and deserpidine.
3.2 Traditional and Historical Use
Native to India, Rauwolfia has been used as a traditional Ayurvedic medicine for many ailments, including anxiety, headaches, and snakebites, and as a general sedative for more than 1,000 years.
Various parts of this plant have been used in traditional medicine (Ayurvedic medicine) for centuries to treat a variety of ailments including snake bites, fever, general weakness, insomnia, intestinal diseases, liver problems, vertigo, and even mental illness.
Its roots, containing indole alkaloids, have been used as a crude drug to treat hypertension, mental disorders, and snake bites. The isolation of reserpine from R. serpentina, in the mid-twentieth century, revolutionized hypertension treatment and contributed to modern neuropsychopharmacology.
3.3 Key Phytochemical Constituents
The various phytochemical compounds or secondary metabolites present in R. serpentina include alkaloids, phenols, tannins, and flavonoids. About 80 alkaloids have been isolated from Rauwolfia species; they include ajmaline, ajmalimine, ajmalicine, deserpidine, indobine, indobinine, reserpine, reserpiline, rescinnamine, rescinnamidine, serpentine, serpentinine, yohimbine, and numerous others.
The root of Rauwolfia serpentina (snakeroot) contains numerous alkaloids, of which reserpine and rescinnamine are said to be the most active as hypotensive agents.
The plant's complex chemical composition of over 50 alkaloids, flavonoids, tannins, and other bioactive compounds is influenced by geographic location, age, and seasonal changes. This chemical diversity enhances its therapeutic potential but challenges quality control and standardization.
3.4 Mechanisms of Action
The antihypertensive properties of R. serpentina are attributed to reserpine (3,4,5-trimethyl benzoic acid ester of reserpic acid, an indole derivative of 18-hydroxy yohimbine type). It is the most prominent of all its alkaloids and is a natural tranquilizer. Reserpine functions as a sympatholytic agent and antihypertensive medication by acting as an adrenergic uptake inhibitor. Reserpine binds to the storage vesicles of catecholamines, such as dopamine and norepinephrine.
Reserpine and related alkaloids in Indian snakeroot deplete monoamine neurotransmitters (norepinephrine, dopamine, serotonin) by blocking their uptake into synaptic vesicles. This depletion reduces sympathetic nervous system activity, leading to vasodilation and decreased heart rate. The ajmaline alkaloid acts as a sodium channel blocker, potentially affecting cardiac rhythm through Class IA antiarrhythmic activity.
Its diverse alkaloids are responsible for many notable pharmacological activities, especially the active root-alkaloid reserpine. Psychopharmacological research has principally described reserpine for sedation.
3.5 Scientific Evidence by Area of Use
3.5.1 Hypertension
Much of the medicinal effects of Rauwolfia serpentina and Rauwolfia vomitoria have been attributed to the hypotensive indole alkaloid reserpine. Before the advent of current pharmaceutical options for hypertension (beta blockers, calcium channel blockers, and angiotensin-converting inhibitors), reserpine was a mainstay in the management of hypertension.
In a referenced study, a daily dose of one to three Serpina tablets was well tolerated. The product caused sedation and usually improved sleep, and it promoted moderate hypotension, particularly in labile patients with hypertension and tachycardia. It also seemed to have a sympatholytic effect, but did not produce postural hypotension. A Cochrane meta-analysis of a Rauwolfia randomized controlled trial on human hypertension has been cited in the literature. Reserpine derived from this plant was historically an approved pharmaceutical antihypertensive, but has been largely supplanted by newer drug classes with improved side-effect profiles.
Limited modern clinical research exists on Rauvolfia serpentina as a whole-plant supplement. Available commentary explicitly notes there is limited good scientific evidence to support the traditional uses of Rauwolfia serpentina as a botanical supplement in contemporary contexts.
Evidence strength: The isolated alkaloid reserpine has well-established pharmacological antihypertensive effects documented in the mid-20th century pharmaceutical literature. Evidence for the whole root as a supplement in modern clinical terms is limited and not robustly studied by contemporary RCT standards.
3.5.2 Anxiety and Insomnia
R. serpentina is mainly considered effective in the treatment of hypertension and psychotic disorders like anxiety, insomnia, and schizophrenia based on its alkaloid chemistry and traditional use. However, these applications in the context of the whole-plant supplement lack rigorous modern randomized controlled trial support separate from the historical pharmaceutical work on reserpine.
3.6 Safety Considerations
Inexpert use of R. serpentina can lead to serious toxicity, including symptoms such as hypotension, sedation, depression, and potentiation of other central depressants. Because reserpine depletes monoamine neurotransmitters, its use is associated with a clinically significant risk of depression — a recognized adverse effect that historically limited reserpine's use as a pharmaceutical agent. The whole-root supplement carries these same pharmacologically plausible risks.
4. Seneca / Senega Snakeroot (Polygala senega)
4.1 Botanical Identity and Common Forms
Polygala senega L. (synonyms: Polygala senegum L.; P. rosea Steud; Senega officinalis Spach) is commonly known as snakeroot or milkwort, belonging to the family Polygalaceae. The name "Senega" originated from the Seneca tribe of North American Indians. The plant is indigenous to North America, found in eastern United States, Virginia, southern Canada, western New England, Wisconsin, and Kentucky.
The root also contains a small amount of methyl salicylate, which is responsible for its characteristic wintergreen scent. It is also used as an ingredient in cough syrups, teas, lozenges, and gargles.
4.2 Traditional and Historical Use
Senega root was used by eastern American Indian tribes, including the Seneca tribe (from whom its name is derived), to treat rattlesnake bites; however, early European observers gave little credence to this use. Colonists and Europeans used senega root as an emetic, cathartic, diuretic, and diaphoretic, and in treatment of pulmonary diseases (such as pneumonia, asthma, and pertussis), gout, and rheumatism. Its main use in the 19th century was as an expectorant cough remedy.
Senega root was included in the US Pharmacopeia from 1820 to 1936 and in the National Formulary from 1936 to 1960.
The root has been popular in traditional North American herbal medicine where it was used as an expectorant, diuretic, as well as an anti-inflammatory and a medicine to treat toothaches.
4.3 Key Phytochemical Constituents
The major constituents of P. senega are triterpenoid saponins such as senegin, polygalic acid, senegenin, presenegenin, and senegenic acid, as well as fixed oil.
Seneca snakeroot contains a series of saponins constructed from the 2,3,27-trihydroxy-oleanane 23,28-dioic acid triterpene skeleton (presenegenin), with a single sugar attached. The senegins can be analyzed by high-performance liquid chromatography. Several other species of Polygala contain distinct but very similar saponins based on the same sapogenin. An extensive series of ester oligosaccharides, senegoses A through O, have also been isolated from P. senega var. latifolia.
4.4 Mechanisms of Action
The roots of P. senega, native to North America, form the basis of the well-known traditional herbal medicine known as Seneca snakeroot (Polygala radix). They are used for their expectorant, diuretic, and anti-inflammatory properties, attributed to saponins and oligosaccharide multi-esters. Triterpenoid saponins are thought to irritate the gastric mucosa, triggering a reflex increase in respiratory tract secretions — the proposed basis of the expectorant action, a mechanism common to saponin-containing expectorants.
4.5 Scientific Evidence by Area of Use
4.5.1 Respiratory / Expectorant Use
The roots are used as stimulant and expectorant in bronchitis. However, robust human clinical trial evidence for senega root as an expectorant is sparse. The chemical and pharmacological evidence needed to support the medical applications of this plant, especially for its use as an expectorant, dates from the early part of the last century and needs further confirmation.
Evidence strength: Traditional and pharmacopoeial use is well documented, but modern clinical trial evidence is absent. The expectorant mechanism is pharmacologically plausible based on saponin chemistry.
4.5.2 Vaccine Adjuvant Potential (Preclinical)
Saponins isolated from Polygala senega L. (Polygalaceae) had potential vaccine adjuvant activity, increasing specific immune responses in mice immunized with ovalbumin and in hens immunized with rotavirus. This is a preclinical finding without current human translation.
4.6 Safety Considerations
High doses of powdered senega root or tincture are emetic and irritating to the GI tract. Gastrointestinal irritation is the primary dose-dependent adverse effect, consistent with the irritant properties of saponins. The root is contraindicated during pregnancy and nursing, and in individuals with gastritis or peptic ulcer disease, consistent with its GI irritant profile.
5. White Snakeroot (Ageratina altissima) — Critical Disambiguation
White snakeroot is not used as a dietary supplement and is not safe for human consumption. It is included here solely to prevent dangerous confusion with the medicinally used species described above.
Ingestion of white snakeroot (Ageratina altissima) can cause trembles in livestock and milk sickness in humans. The toxicity has been associated with tremetol, a relatively crude, multicomponent lipophilic extract of the plant.
White snakeroot (Ageratina altissima) is a sporadically toxic plant that causes trembles in livestock and milk sickness in humans who drink tainted milk. Historically, milk sickness — a potentially fatal disease — was caused by humans consuming milk from cattle that had grazed on white snakeroot.
High-performance liquid chromatography (HPLC) analysis indicated that there are three different chemotypes of white snakeroot from the plant samples analyzed. Elucidation of these chemotypes may explain the sporadic and unpredictable toxicity of white snakeroot to livestock and humans.
Results of animal research demonstrate for the first time that white snakeroot is a potent myotoxin in goats, and that other compound(s), which may be lost or modified during the extraction process, could be involved in causing trembles and milk sickness.
6. Body Systems and Health Areas Associated with Snakeroot
- Reproductive / Endocrine System (Black Snakeroot): Menopausal vasomotor symptoms, dysmenorrhea, premenstrual syndrome, uterine function — the primary clinical application with the greatest evidence base, though results remain mixed.
- Cardiovascular System (Indian Snakeroot): Hypertension and cardiac arrhythmia (via reserpine and ajmaline alkaloids); historically significant as a pharmaceutical source.
- Central Nervous System (Indian Snakeroot; Black Snakeroot): Sedation, anxiety, and mood regulation (Indian snakeroot via monoamine depletion; black snakeroot via serotonergic and opioidergic pathways).
- Respiratory System (Senega Snakeroot): Expectorant use in bronchitis, asthma, pertussis, and other respiratory conditions — pharmacopoeially recognized, though clinical evidence is dated.
- Musculoskeletal System (Black Snakeroot): Rheumatic pain and inflammation — traditional use, no modern clinical evidence.
- Skeletal / Bone (Black Snakeroot): Preclinical anti-osteoclastic activity; no clinical trial confirmation in humans.
- Immune System (Senega Snakeroot): Vaccine adjuvant potential in preclinical models only.
7. Summary of Dosage Forms Reported in Sources
Black Snakeroot (Actaea racemosa)
- Numerous clinical trials and review articles indicate that 40–80 mg daily of a standardized extract improves menopausal symptoms such as hot flashes.
- A higher dose of 128 mg/day standardized to 7.27 mg of triterpene glycosides (ethanolic extract) was used in at least one study with no serious adverse events reported.
- A 75% ethanol extract standardized to 5.6% active triterpene glycosides has been used in a Phase II NIH-supported clinical trial.
Senega Snakeroot (Polygala senega)
- Traditional and pharmacopoeial preparations include decoctions, fluid extracts, syrups, tinctures, and lozenges, with the root listed in the US Pharmacopeia from 1820 to 1936.
8. Consolidated Safety Considerations and Known Interactions
Black Snakeroot (Actaea racemosa)
- Black cohosh is well tolerated and is generally safe. Some insignificant side effects, such as nausea, vomiting, headaches, and dizziness, have been reported.
- No evidence of hepatotoxicity was found in systematic reviews of clinical trials of chemically standardized black cohosh preparation; regardless of dosage, no liver function markers were altered. However, the USP recommends hepatotoxicity labeling based on case reports, and causality remains contested.
- Patients taking black cohosh could be at risk for developing rhabdomyolysis and serotonin toxicity if they are also taking other serotonergic agents.
- Black cohosh inhibits CYP3A4 and CYP2D6, enzymes responsible for metabolizing a wide range of medications including certain antidepressants, antipsychotics, and opioids.
- Contraindicated in patients with aspirin sensitivity, liver disease, hormone-sensitive cancers, stroke, or high blood pressure.
- Black cohosh may not be safe for use during pregnancy or while breastfeeding.
Indian Snakeroot (Rauwolfia serpentina)
- Inexpert use of R. serpentina can lead to serious toxicity, including symptoms such as hypotension, sedation, depression, and potentiation of other central depressants.
- Monoamine-depleting properties of reserpine carry a clinically significant risk of depression; this was historically a major limitation of reserpine as a pharmaceutical agent and applies pharmacologically to the whole-root supplement.
- The ajmaline alkaloid acts as a sodium channel blocker with Class IA antiarrhythmic activity, creating risk of cardiac interactions with other antiarrhythmic or QT-prolonging agents.
Senega Snakeroot (Polygala senega)
- High doses of powdered senega root or tincture are emetic and irritating to the GI tract.
- Contraindicated in gastritis, peptic ulcer, and during pregnancy and nursing — consistent with the irritant saponin profile and the plant's historical classification as an emetic at high doses.
References
Go back